KPMG
30.6.2021 07:02:08 CEST | Business Wire | Press release
In collaboration with KPMG Law, World Commerce & Contracting (WorldCC) surveyed executives from across the globe, gathering insights into the process of contracting across industries ― and how to fix perennial and costly problems in the contract development process.
- Almost 90% of organizations have ineffective and fragmented contracting processes
- 76% of organizations want to prioritize digitalization of contracts
- A potential solution lies in setting up an “Office of Contracting”
The COVID-19 pandemic has highlighted a significant problem with contracts, as revealed by a report released by World Commerce & Contracting (WorldCC) and KPMG Law, entitled Can the contracting process improve without an owner?
For decades, organizations have tried to simplify the contract process―testing and implementing contract management tools and systems, but to little effect. Now, as digitalization gathers pace, streamlining the contract process is a major priority. As the report makes clear, this issue is not isolated to one business or industry type. It is a global problem that is slowing organizations down.
“Contracts directly impact the health and wealth of every organization. Yet, for all their importance, on average, contracts suffer more than 9% value erosion ,” says Jason McQuillen , a partner in KPMG Law in Australia, head of its Legal Operations Transformation business and report co-author. “They only gain executive attention when things go wrong, and the focus is on who to blame. The dominant, widely acknowledged reason for this is simple: no one owns the contract delivery process .”
Only 10.8% of organizations consider their end-to-end contracting process to be “very effective.” As one research respondent commented, “Getting a contract is like having a root canal.” Cost was also an area of contention among respondents, with the least efficient processes reportedly averaging more than US$10,000 per contract, simply for reviewing and processing activities.
Tim Cummins , WorldCC President and report co-author, comments: “Contracting has never been addressed effectively. The report highlights a clear frustration with departments involved in the contracting process, lengthy cycle times, and CEOs believe they are losing money.”
Focus on digitalization
Digitalization of the contracting process is now a priority for 76% of respondents, yet only 26% of respondents believe that their technology team is well equipped to support their digitalization initiative. Digitalization alone cannot fix the broader issues.
“I’m optimistic that the impact of the pandemic will encourage organizations to change things, and digitalizing contracting is now a business priority,” says Nicola Brooks , Director for KPMG Law in the UK, head of its Legal Operations Transformation business and report co-author. “But most organizations will not succeed by focusing on this in isolation. Rather, to succeed, organizations need to have an operating model as part of this.”
What’s the solution?
The report concludes that sustained progress and improving the quality of the contracting process depends on achieving a single point of process ownership and accountability. WorldCC and KPMG Law say that introducing an ‘Office of Contracting’ within each organization is the solution to tackling a fragmented and costly process. The OOC would be a small group responsible for all contracts across the enterprise and the process surrounding it. They would work in harmony with the multiple functions, coordinating and coalescing.
Stuart Fuller , Global Head of Legal Services at KPMG, concludes: “The WorldCC and KPMG Law report shows that there is a clear problem in the contracting process. The solution needs clear ownership within the organization, and external support from trusted advisers with real, global experience in this critical area for business, who can drive value creation and end the value erosion.”
About the research:
The report is based on input received from a series of round-table discussions and an on-line survey conducted by World Commerce & Contracting in the period from January to March 2021.
More than 40 executives participated in the roundtables and shared their views on the key trends in commercial and contract management. This was supplemented by input from more than 300 survey respondents, together representing a range of industry and geographic perspectives and size of organization. While taking account of all responses, the report focuses primarily on the 200 organizations with annual revenues of more than US$500 million since the complexities being examined are strongly related to the size of the business.
About KPMG International
KPMG is a global organization of independent professional services firms providing Audit, Tax and Advisory services. We operate in 146 countries and territories and in FY20 had close to 227,000 people working in member firms around the world. Each KPMG firm is a legally distinct and separate entity and describes itself as such. KPMG International Limited is a private English company limited by guarantee. KPMG International Limited and its related entities do not provide services to clients. More: home.kpmg .
About World Commerce & Contracting
World Commerce & Contracting is a not for profit association and the only global body promoting standards and raising capabilities in commercial practice.
The organization works to inspire individuals and organizations through research and ideas and equips its members with knowledge and networks that support successful contracts and commercial relationships. More: worldcc.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005212/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
